Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

Blackstone joins other big investors such as ARCH Venture Partners and Bain Capital Life Sciences in pumping billions of ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.

Senators on the Health, Education, Labor, and Pensions committee were critical of Kennedy’s long history as an anti-vaccine campaigner.

While the Chicago metropolitan area is not a major life sciences hub, a recent Cushman & Wakefield report predicts the ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

Kennedy’s confirmation hearing on Wednesday became heated as Democratic senators grilled the nominee for HHS Secretary on his ...

Roche will continue a careful approach to high-priced deals, putting science at the center of its business development ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.